List of Figures
Figure 1: Type 2 Diabetes Mellitus, Global, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987–2014 7
Figure 2: Type 2 Diabetes Mellitus, Global, Post-Marketing-Approval Sales Performance of First-in-Class and Non-First-in-Class Products Across Pharmaceutical Industry ($m), 2006–2013 8
Figure 3: Type 2 Diabetes Mellitus, Global, Market by Molecule Type and Molecular Target, 2018 21
Figure 4: Type 2 Diabetes Mellitus, Global, Pipeline Size by Therapy Area, 2018 23
Figure 5: Type 2 Diabetes Mellitus, Global, Pipeline by Stage of Development and Molecule Type, 2018 24
Figure 6: Type 2 Diabetes Mellitus, Global Pipeline by Molecular Target and Stage of Development, 2018 25
Figure 7: Type 2 Diabetes Mellitus, Global, Pipeline Breakdown of GPCR and Protein Kinase Molecular Target Class, 2018 25
Figure 8: Type 2 Diabetes Mellitus, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2018 26
Figure 9: Type 2 Diabetes Mellitus, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2018 27
Figure 10: Type 2 Diabetes Mellitus, Global, Percentage Distribution of First-in-Class and Non-First-in-class Pipeline Programs by Stage of Development and Molecular Target Class, 2018 28
Figure 11: Type 2 Diabetes Mellitus, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018 29
Figure 12: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 1) 30
Figure 13: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 2) 31
Figure 14: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 3) 32
Figure 15: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 4) 33
Figure 16: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 5) 34
Figure 17: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 6) 34
Figure 18: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 7) 35
Figure 19: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 8) 35
Figure 20: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 9) 36
Figure 21: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 10) 36
Figure 22: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 11) 37
Figure 23: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 12) 38
Figure 24: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Matrix Assessment for Type 2 Diabetes Mellitus, 2018 (part 1) 41
Figure 25: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Matrix Assessment for Type 2 Diabetes Mellitus, 2018 (part 2) 42
Figure 26: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Matrix Assessment for Type 2 Diabetes Mellitus, 2018 (part 2) 43
Figure 27: Type 2 Diabetes Mellitus, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006–2015 57
Figure 28: Type 2 Diabetes Mellitus, Global, Industry-Wide Licensing Deals by First-in-Class Status, Deal Value, Upfront Payment Value and Stage of Development, 2006–2014 58
Figure 29: Type 2 Diabetes Mellitus, Global Licensing Deals by Region, Value and Year 2006–2018 59
Figure 30: Type 2 Diabetes Mellitus, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018 59
Figure 31: Type 2 Diabetes Mellitus, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target Class, 2006–2018 60
Figure 32: Type 2 Diabetes Mellitus, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 61
Figure 33: Type 2 Diabetes Mellitus, Global, Co-development Deals by Region, Value and Year 2006–2018 62
Figure 34: Type 2 Diabetes Mellitus, Global, Number and Aggregate Deal Value of Co-development Deals By Stage of Development and Year, 2006–2018 63
Figure 35: Type 2 Diabetes Mellitus, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018 64
Figure 36: Type 2 Diabetes Mellitus, Global, Co-development Deals with Disclosed Deal Values, 2006–2018 65
Figure 37: Type 2 Diabetes Mellitus, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 1) 66
Figure 38: Type 2 Diabetes Mellitus, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 2) 67
Figure 39: Type 2 Diabetes Mellitus, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 3) 68